DOPAMINE AGONISTS IN PARKINSON’S DISEASE THERAPY – 15 YEARS OF EXPERIENCE

What is it about?

DOPAMINE AGONISTS IN PARKINSON’S DISEASE THERAPY – 15 YEARS OF EXPERIENCE OF THE NEUROLOGICAL CLINICS FROM TÎRGU MUREș. A CROSS-SECTIONAL STUDY Szász JA, MD; Constantin V, MD; Mihály I, MD; Biró I; Péter Cs; Orbán-Kis K, MD; Szatmári Sz, MD Ideggyogy Sz 2019;72(5–6):187–193. Background and purpose – There is relatively few data regarding the usage of dopaminagonists for the treatment of Parkinson’s disease; furthermore, there are no publications regarding Central- and Eastern-European countries. The aim of the study was to evaluate the use of dopamine agonists as a therapeutic option amongst Parkinson’s disease patients admitted to the Neurological Clinics of Tîrgu Mures during the last 15 years. Methods – In our study we investigated the data of all Parkinson’s patients treated at our clinics between the 1st of January 2003 and the 31st of December 2017. We analyzed the particularities of dopamine agonists’ usage based on the therapeutic recommendations from the final report of these patients. Regarding time since the diagnosis, we divided the patients in two groups: less than or equal to 5 years and more than 5 years. Results – During the studied period a total of 2379 patients with Parkinson’s disease were treated at the Clinics. From the 1237 patients with disease duration under 5 years 665 received dopamine agonists: 120 as monotherapy, 83 together with monoamine oxidase inhibitors and in 234 cases associated with levodopa. The remaining 228 patients were treated with a triple combination of levodopa, dopamine agonists and monoamine oxidase inhibitors. In patients suffering from Parkinson’s disease for more than 5 years, in 364 cases out of 653 a dopamine agonist was part of the therapy.

Featured Image